Details of the Drug
General Information of Drug (ID: DMZF4IC)
Drug Name |
1,2-Bis-(2-chloro-phenyl)-ethane-1,2-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2,2'-Dichlorobenzil; 21854-95-5; 1,2-bis(2-chlorophenyl)ethane-1,2-dione; 2,2'-Dichlorodibenzoyl; Ethanedione, bis(2-chlorophenyl)-; Benzil, 2,2'-dichloro-; MFCD00018263; 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-; AE-562/43458948; NSC114829; Benzil,2'-dichloro-; ACMC-20aok0; AC1Q5FHJ; Benzil-based compound, 10; Bis(2-chlorophenyl) diketone; 2,2'-Dichlorobenzil, 97%; SCHEMBL2156567; CHEMBL365392; AC1L3H37; DTXSID1066736; CTK4E7789; BDBM22732; VOSNNSVWVJFJCR-UHFFFAOYSA-N; MolPort-003-915-120; ZINC1704748; Benzil, 2,2'-dichloro- (8CI)
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 279.1 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||